These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Ernest Pharmaceuticals team of scientists has made “exciting,” patient-friendly advances in developing a non-toxic bacterial ...
The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback